Related Experiment Video
Updated: Aug 23, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Design, synthesis, biological activity and computational simulation evaluation of pyrimidine-2-aminoacetamide
Yi-Xuan Wang1, Shi-Hao Qin1, Qian Liu2
1College of Pharmaceutical Sciences, Institute of Life Science and Green Development, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Hebei University, Baoding, 071002, China.
Abstract:
To search for novel anti-Alzheimer's disease candidate molecules, a series of pyrimidine-2-aminoacetamide derivatives were designed and synthesized, and their cholinesterase (ChE) inhibitory activities were systematically evaluated. The results showed that all target compounds exhibited varying degrees of inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Among them, compound 17v had the most excellent activity, with IC50 values of 0.96 and 7.12 μM for AChE and BuChE, respectively, which were superior to the positive control galantamine (AChE: IC50 = 5.10 μM, BuChE: IC50 = 14.76 μM). In terms of antioxidant activity, the results indicated that the overall activity of all compounds was relatively weak, with the most active compound 17d having an IC50 value of 115.77 μM, which was inferior to ascorbic acid (IC50 = 41.17 μM). Molecular docking revealed that 17v binds to both catalytic and peripheral anionic sites of AChE, supporting a mixed-type inhibition mechanism confirmed by enzyme kinetics. A 100 ns molecular dynamics simulation confirmed stable binding of 17v within AChE and BuChE pockets. Target prediction and toxicity assessment suggested that compound 17v may possess multi-target neuroprotective potential and a favorable preliminary safety profile, supporting its further investigation as a potential therapeutic candidate for Alzheimer's disease. SwissADMET prediction indicated favorable physicochemical properties and drug-likeness profiles. In conclusion, compound 17v represents a promising lead compound for anti-Alzheimer's therapy.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Direct-Acting Cholinergic Agonists: Pharmacokinetics
